Guangzhou Baiyunshan Pharmaceutical Holdings Company (874) Q2 2026 earnings summary

Executive summary

• Operating revenue for the first half of 2026 was RMB42.09 billion, up 0.61% year-over-year, while net profit attributable to shareholders fell 16.70% to RMB2.10 billion.

• The group focused on biopharmaceuticals, healthcare, and innovation, expanding its product portfolio, R&D pipeline, and international presence.

• Major activities included procurement reforms, product launches, digital transformation, and capital operations such as M&A and venture investments.

Financial highlights

• Operating revenue: RMB42.09 billion (+0.61% YoY); net profit attributable to shareholders: RMB2.10 billion (−16.70% YoY).

• Basic EPS: RMB1.289 (−16.70% YoY); gross profit margin: 17.10% (down 1.09 percentage points YoY).

• Net cash flow from operating activities: −RMB269.95 million (improved from −RMB3.40 billion YoY).

• Total assets: RMB87.82 billion (+3.92% from end-2025); net assets attributable to shareholders: RMB39.13 billion (+3.56%).

Outlook and guidance

• Plans for H2 2026 include strengthening core business, accelerating R&D and innovation, expanding overseas, intensifying capital operations, and deepening digital transformation.

• Focus on flagship products, new product launches, and international market penetration, especially in Vietnam, Malaysia, and Central Asia.